About 50% of patients with sepsis show myocardial involvement characterized by biventricular enlargement, reduced contractility and diastolic dysfunction. This increases the risk of death and leads to an extremely poor prognosis in the case of severe sepsis or septic shock, with full recovery of cardiac function seen in survivors at 7-10 days. The pathogenesis of myocardial dysfunction has long been investigated and, although it is still not fully understood, seems not to be due to reduced coronary flow, but to circulating substances released by pathogens (e.g. endotoxins) and host immuno-inflammatory responses (e.g. cytokines and mechanisms related to nitric oxide). First-line therapy is causal and consists of antibiotics plus the surgical excision of the infectious focus; in the presence of severe sepsis or septic shock, it is also necessary to promptly start circulatory and multiorgan support treatment. This review describes current knowledge concerning the instrumental and clinical characteristics, pathophysiology, prognosis and therapy of myocardial dysfunction during sepsis, and briefly considers possible future therapeutic perspectives. © 2011 Il Pensiero Scientifico Editore.

[Myocardial dysfunction during sepsis: epidemiology, prognosis and treatment]. FT Disfunzione miocardica in corso di sepsi: epidemiologia, significato prognostico e trattamento / Paoli, Giorgia; Valente, Serafina; Ardissino, D; Gensini Gian, Franco. - In: GIORNALE ITALIANO DI CARDIOLOGIA. - ISSN 1827-6806. - 12:12(2011), pp. 804-814. [10.1714/996.10825]

[Myocardial dysfunction during sepsis: epidemiology, prognosis and treatment]. FT Disfunzione miocardica in corso di sepsi: epidemiologia, significato prognostico e trattamento

Ardissino D;
2011-01-01

Abstract

About 50% of patients with sepsis show myocardial involvement characterized by biventricular enlargement, reduced contractility and diastolic dysfunction. This increases the risk of death and leads to an extremely poor prognosis in the case of severe sepsis or septic shock, with full recovery of cardiac function seen in survivors at 7-10 days. The pathogenesis of myocardial dysfunction has long been investigated and, although it is still not fully understood, seems not to be due to reduced coronary flow, but to circulating substances released by pathogens (e.g. endotoxins) and host immuno-inflammatory responses (e.g. cytokines and mechanisms related to nitric oxide). First-line therapy is causal and consists of antibiotics plus the surgical excision of the infectious focus; in the presence of severe sepsis or septic shock, it is also necessary to promptly start circulatory and multiorgan support treatment. This review describes current knowledge concerning the instrumental and clinical characteristics, pathophysiology, prognosis and therapy of myocardial dysfunction during sepsis, and briefly considers possible future therapeutic perspectives. © 2011 Il Pensiero Scientifico Editore.
2011
[Myocardial dysfunction during sepsis: epidemiology, prognosis and treatment]. FT Disfunzione miocardica in corso di sepsi: epidemiologia, significato prognostico e trattamento / Paoli, Giorgia; Valente, Serafina; Ardissino, D; Gensini Gian, Franco. - In: GIORNALE ITALIANO DI CARDIOLOGIA. - ISSN 1827-6806. - 12:12(2011), pp. 804-814. [10.1714/996.10825]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11381/2883841
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 7
  • ???jsp.display-item.citation.isi??? ND
social impact